Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Сравнение различных режимов терапии госпитализированных пациентов с внебольничной пневмонией
Сравнение различных режимов терапии госпитализированных пациентов с внебольничной пневмонией
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Гильманов А.А., Визель А.А., Малышева И.Ю. и др. Анализ эффективности лечения и причин летальных исходов при внебольничной пневмонии в Республике Татарстан. Пробл. туб. 2002; 7: 26–30.
2. Илькович М.М. Опыт применения азитромицина (Сумамеда) при внегоспитальных пневмониях. Пульмонология.1998; 2: 89–91.
3. Синопальников А.И., Первов Ю.А., Богданов М.Б., Раков А.Л. Пилотное исследование длительной профилактики азитромицином острых бактериальных инфекций дыхательных путей у военнослужащих. Клин. микробиол. антимикроб. химиотер. 2000; 2 (1): 31–6.
4. Чучалин А.Г., Синопальников А.И., Козлов Р.С. и др. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. РРО, МАКМАХ. М., 2010.
5. Contopoulos-Ioannidis DG, Ioannidis JP, Chew P, Lau J. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. J Antimicrob Chemother 2001; 48 (5): 691–703.
6. Fok MC, Kanji Z, Mainra R, Boldt M. Characterizing and developing strategies for the treatment of community-acquired pneumonia at a community hospital. Can Respir J 2002; 9 (4): 247–52.
7. Frei CR, Bell AM, Traugott KA et al. A clinical pathway for community-acquired pneumonia: an observational cohort study. BMC Infect Dis 2011; 11: 188.
8. Griffin AT, Peyrani P, Wiemken T, Arnold F. Macrolides versus quinolones in Legionella pneumonia: results from the Community-Acquired Pneumonia Organization international study.
Int J Tuberc Lung Dis 2010; 14 (4): 495–99.
9. Hess G, Hill JW, Raut MK et al. Comparative antibiotic failure rates in the treatment of community-acquired pneumonia: Results from a claims analysis. Adv Ther 2010; 27 (10): 743–55.
10. Lutz L, Pereira DC, Paiva RM et al. Macrolides decrease the minimal inhibitory concentrations of anti-pseudomonal agents against Pseudomonas aeruginosa from cystic fibrosis patients in biofilm. BMC Microbiol 2012; 12 (1): 196.
11. Todisco T, Dal Farra F, Ciliberti G et al. An Italian experience of sequential intravenous and oral azithromycin plus intravenous ampicillin/sulbactam in hospitalized patients with community-acquired pneumonia. J Chemother 2008; 20 (2): 225–32.
12. van Delden C, Köhler T, Brunner-Ferber F et al. Azithromycin to prevent Pseudomonas aeruginosa ventilator-associated pneumonia by inhibition of quorum sensing: a randomized controlled trial. Intensive Care Med 2012; 38 (7): 1118–25.
13. Vaz AP, Morais A, Melo N et al. Azithromycin as an adjuvant therapy in cryptogenic organizing pneumonia. Rev Port Pneumol 2011; 17 (4): 186–9.
14. Walkey AJ, Wiener RS. Macrolide antibiotics and survival in patients with acute lung injury. Chest 2012; 141 (5): 1153–9.
15. Wang D, Wang Y, Liu YN. Activity of ciprofloxacin and azithromycin on biofilms produced in vitro by Haemophilus influenza. Chin Med J (Engl) 2009; 122 (11): 1305–10.
16. Wierzbowski AK, Hoban DJ, Hisanaga T et al. The use of macrolides in treatment of upper respiratory tract infections Curr Allergy Asthma Rep 2006; 6 (2): 171–81.
17. Woodhead M, Blasi F, Ewig S et al. Guidelines for the management of adult lower respiratory tract infections. Ed. D.Raoult.
Clin Microbiol Infect 2011; 17 (Suppl. 6): 1–24.
18. Yanagihara K, Izumikawa K, Higa F et al. Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection Intern Med 2009; 48 (7): 527–35.
19. Zarogoulidis P, Papanas N, Kioumis I et al. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol 2012; 68 (5): 479–503.
20. Zervos M, Mandell LA, Vrooman PS et al. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia. Treat Respir Med 2004; 3 (5): 329–36.
2. Илькович М.М. Опыт применения азитромицина (Сумамеда) при внегоспитальных пневмониях. Пульмонология.1998; 2: 89–91.
3. Синопальников А.И., Первов Ю.А., Богданов М.Б., Раков А.Л. Пилотное исследование длительной профилактики азитромицином острых бактериальных инфекций дыхательных путей у военнослужащих. Клин. микробиол. антимикроб. химиотер. 2000; 2 (1): 31–6.
4. Чучалин А.Г., Синопальников А.И., Козлов Р.С. и др. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. РРО, МАКМАХ. М., 2010.
5. Contopoulos-Ioannidis DG, Ioannidis JP, Chew P, Lau J. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. J Antimicrob Chemother 2001; 48 (5): 691–703.
6. Fok MC, Kanji Z, Mainra R, Boldt M. Characterizing and developing strategies for the treatment of community-acquired pneumonia at a community hospital. Can Respir J 2002; 9 (4): 247–52.
7. Frei CR, Bell AM, Traugott KA et al. A clinical pathway for community-acquired pneumonia: an observational cohort study. BMC Infect Dis 2011; 11: 188.
8. Griffin AT, Peyrani P, Wiemken T, Arnold F. Macrolides versus quinolones in Legionella pneumonia: results from the Community-Acquired Pneumonia Organization international study.
Int J Tuberc Lung Dis 2010; 14 (4): 495–99.
9. Hess G, Hill JW, Raut MK et al. Comparative antibiotic failure rates in the treatment of community-acquired pneumonia: Results from a claims analysis. Adv Ther 2010; 27 (10): 743–55.
10. Lutz L, Pereira DC, Paiva RM et al. Macrolides decrease the minimal inhibitory concentrations of anti-pseudomonal agents against Pseudomonas aeruginosa from cystic fibrosis patients in biofilm. BMC Microbiol 2012; 12 (1): 196.
11. Todisco T, Dal Farra F, Ciliberti G et al. An Italian experience of sequential intravenous and oral azithromycin plus intravenous ampicillin/sulbactam in hospitalized patients with community-acquired pneumonia. J Chemother 2008; 20 (2): 225–32.
12. van Delden C, Köhler T, Brunner-Ferber F et al. Azithromycin to prevent Pseudomonas aeruginosa ventilator-associated pneumonia by inhibition of quorum sensing: a randomized controlled trial. Intensive Care Med 2012; 38 (7): 1118–25.
13. Vaz AP, Morais A, Melo N et al. Azithromycin as an adjuvant therapy in cryptogenic organizing pneumonia. Rev Port Pneumol 2011; 17 (4): 186–9.
14. Walkey AJ, Wiener RS. Macrolide antibiotics and survival in patients with acute lung injury. Chest 2012; 141 (5): 1153–9.
15. Wang D, Wang Y, Liu YN. Activity of ciprofloxacin and azithromycin on biofilms produced in vitro by Haemophilus influenza. Chin Med J (Engl) 2009; 122 (11): 1305–10.
16. Wierzbowski AK, Hoban DJ, Hisanaga T et al. The use of macrolides in treatment of upper respiratory tract infections Curr Allergy Asthma Rep 2006; 6 (2): 171–81.
17. Woodhead M, Blasi F, Ewig S et al. Guidelines for the management of adult lower respiratory tract infections. Ed. D.Raoult.
Clin Microbiol Infect 2011; 17 (Suppl. 6): 1–24.
18. Yanagihara K, Izumikawa K, Higa F et al. Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection Intern Med 2009; 48 (7): 527–35.
19. Zarogoulidis P, Papanas N, Kioumis I et al. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol 2012; 68 (5): 479–503.
20. Zervos M, Mandell LA, Vrooman PS et al. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia. Treat Respir Med 2004; 3 (5): 329–36.
Авторы
А.А.Визель, Г.В.Лысенко
Кафедра фтизиопульмонологии ГБОУ ВПО Казанский государственный медицинский университет Минздрава РФ
Кафедра фтизиопульмонологии ГБОУ ВПО Казанский государственный медицинский университет Минздрава РФ
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.